RecruitingNCT07425171

Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion

Safety and Effectiveness of GENOSS PCB (Paclitaxel-coated Balloon) in Patients With Long Femoropopliteal Lesion: A Prospective, Multicenter, Observational Study (GENOSS-PCB Long)

Sponsor

Genoss Co., Ltd.

Enrollment

300 participants

Start Date

Apr 13, 2026

Study Type

OBSERVATIONAL

Conditions

Femoropopliteal Artery Disease PTA (Percutaneous Transluminal Angioplasty)Long Femoropopliteal Artery Disease

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of GENOSS PCB in patients with long femoropopliteal lesions who underwent percutaneous transluminal angioplasty using GENOSS PCB.

Eligibility

Min Age: 19 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with femoropopliteal artery disease, long femoropopliteal artery disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07425171

Related Trials

Combination Therapy of Atherectomy Plus Drug-coated Balloon Versus Drug-coated Balloon for Complex Femoropopliteal Artery Disease

NCT053072631 location